Beata Kuklinska
Overview
Explore the profile of Beata Kuklinska including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
13
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mojsak D, Debczynski M, Kuklinska B, Minarowski L, Kasiukiewicz A, Moniuszko-Malinowska A, et al.
Int J Environ Res Public Health
. 2023 Jan;
20(2).
PMID: 36674340
The COVID-19 pandemic poses a challenge to health systems worldwide. Limiting healthcare availability may delay early diagnosis and worsen the treatment effects of various diseases, including oncological diseases. We analyzed...
2.
Debczynski M, Mojsak D, Kuklinska B, Mroz R
Am J Case Rep
. 2022 Aug;
23:e936536.
PMID: 35949112
BACKGROUND Atezolizumab is an immune checkpoint inhibitor used as first-line treatment with carboplatin and etoposide chemotherapy for advanced small cell lung cancer. Immunochemotherapy treatment decisions can be affected by patients'...
3.
Mojsak D, Debczynski M, Kuklinska B, Moniuszko-Malinowska A, Mroz R
Am J Case Rep
. 2022 Jun;
23:e936420.
PMID: 35648729
BACKGROUND Advanced non-small cell lung cancer has poor prognosis and low survival. Immunotherapy with the use of immune checkpoint inhibitors is a relatively new method of treatment that offers a...
4.
Mojsak D, Kuklinska B, Minarowski L, Mroz R
Adv Med Sci
. 2021 Jul;
66(2):381-387.
PMID: 34315013
Background: Patients with Eastern Cooperative Oncology Group Performance Status 2 (ECOG PS 2) are not included in most randomized clinical trials and registry studies. Nevertheless, immune checkpoint inhibitors are registered...
5.
Mojsak D, Kuklinska B, Debczynski M, Mroz R
Contemp Oncol (Pozn)
. 2021 Apr;
25(1):53-56.
PMID: 33911982
Immunotherapy is a new and very promising method of anti-cancer treatment. Unfortunately, not every patient can benefit from this treatment. The Polish drug program determines the selection of patients based...
6.
Kuklinska B, Moniuszko-Malinowska A, Mroz R, Pancewicz S, Zajkowska J
Case Rep Infect Dis
. 2016 May;
2016:6061350.
PMID: 27239354
Introduction. The diagnosis of lung cancer may still be difficult due to the fact that the first symptoms very often mimic symptoms of other diseases. Case Presentation. In this paper...